U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Lamivudine

; ; ; .

Author Information and Affiliations

Last Update: February 28, 2024.

Continuing Education Activity

Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI), is a cornerstone in the therapeutic landscape for managing HIV-1 and hepatitis B infections. This comprehensive activity explores the diverse indications and contraindications for lamivudine across both conditions, elucidating its mechanism of action as a pivotal component in treating these disorders. Healthcare professionals will gain the necessary knowledge to navigate the nuances of lamivudine usage through a detailed examination of pharmacodynamics, pharmacokinetics, and relevant interactions. The program emphasizes the importance of vigilant monitoring to assess treatment responses and manage potential adverse events effectively, enabling the healthcare team to optimize patient care and outcomes in these infectious diseases.

In addition to its established uses, this activity discusses the broader therapeutic scope of lamivudine, including off-label applications where applicable, providing a comprehensive understanding of its clinical utility. By emphasizing the complexities of dosing and relevant interactions, the course prioritizes lamivudine's optimal administration and incorporation into individualized treatment regimens. Illuminating the imperative role of interprofessional collaboration in steering patients through effective monitoring strategies, the program strives to empower healthcare professionals with the necessary insights to navigate challenges in managing patients with HIV and hepatitis B infections. This initiative aims to improve clinical outcomes and enhance patient care by highlighting lamivudine's mechanism of action and adverse event profile.

Objectives:

  • Identify the specific indications for lamivudine in managing HIV-1 and hepatitis B infections, understanding its role within antiretroviral therapy.
  • Screen patients to assess their suitability for lamivudine therapy, considering factors such as viral load, resistance patterns, and liver function tests.
  • Assess the patient's response to lamivudine therapy, monitor viral load, liver function, and potential adverse effects, and adjust treatment based on these assessments.
  • Implement communication with patients about the benefits, potential risks, and expected outcomes of lamivudine therapy, facilitating shared decision-making and promoting adherence.
Access free multiple choice questions on this topic.

Indications

Lamivudine is a prescription nucleoside reverse transcriptase inhibitor (NRTI) that is used in combination with other drugs as antiviral treatment for human immunodeficiency virus type-1 (HIV-1) and as a monotherapy for hepatitis B virus (HBV).[1] Lamivudine reduces viral load and subsequently reduces disease signs and symptoms, increases CD4+ cell count, improves patients' quality of life, and can help prolong life. The ability to reduce viral load rather than eradicate the virus in a human host classifies lamivudine as a virustatic rather than a virucidal agent. Lamivudine is prescribed as part of other combination therapies. Lamivudine is globally crucial as first-line NRTI therapy; it is currently on the World Health Organization's (WHO) "List of Essential Medications."

Lamivudine, also termed 2',3'-dideoxy-3'-thiacytidine or 3TC, was approved to treat HIV-1 in 1995, then for HBV in 1998.[2] The currently manufactured lamivudine (3TC) is an isolated unnatural L-(-) enantiomer more potent and less cytotoxic than the originally studied racemic mixture termed BCH-189.[2] Ensuing studies of lamivudine have shown that it is most efficacious as a monotherapy for HBV as well as in an HIV regimen that includes multiple antiretroviral therapies.[3][4] Lamivudine is used in combination with 2 or more antivirals to prevent rapid mutations that can lead to drug resistance in HIV-1 patients, specifically via the M184V reverse transcriptase single substitution mutation that has shown to occur in as little as 8 weeks of mono- or combination antiviral therapy that contains lamivudine (3TC).[5] 

Treatment of HIV-1 by lamivudine is in combination with lamivudine, raltegravir, or zalcitabine.[6][7] The newest combination approved by the US Food and Drug Administration (FDA) in 2019 includes 300 mg of 3TC and 50 mg of dolutegravir (DTC), an integrase inhibitor. This is considered a complete therapy regimen for adults who are antiretroviral treatment naïve.[8] This newer dual therapy approach is proving just as effective as 3 or 4 drug regimens.[8][9]

As a virustatic agent, lamivudine has been studied as a possible treatment for SARS-CoV. However, lamivudine has not demonstrated effectiveness in treating SARS-CoV in all known published trials and research.[10]

FDA-Approved Indications

  • HIV infection in adults and children
  • Chronic hepatitis B infection in adults and children

Off-Label Uses

  • HIV postexposure prophylaxis
  • Perinatal transmission of hepatitis B prevention
  • HIV infection prophylaxis for high-risk neonates
  • HIV nonoccupational postexposure prophylaxis

Mechanism of Action

Lamivudine is a dideoxynucleoside cytosine analog that inhibits viral DNA synthesis via reverse transcriptase DNA chain termination post phosphorylation. Once inside the cell, lamivudine, 2'-deoxy-3'-thiacytidine, is metabolized to the triphosphate form, lamivudine triphosphate (abbreviated as 3TC-TP or L-TP), and the monophosphate form, lamivudine monophosphate (abbreviated as 3TC-MP or L-MP), during intracellular kinase phosphorylation. Both forms, L-TP and L-MP, inhibit viral DNA synthesis. Lamivudine is advantageous as an antiviral drug because it is primarily not recognized by human polymerase as a substrate. As an L-(-)-nucleoside enantiomer instead of a D-enantiomer, active lamivudine (3TC) is not primarily recognized by human polymerases as a substrate but actively competes with natural cytidine triphosphate to inhibit reverse transcriptase DNA synthesis seen in both HIV-1 and HBV infection.[11] The triphosphate metabolite can also weakly inhibit mammalian DNA polymerase (α and β types) and mitochondrial DNA (mtDNA) polymerase.[12][13] There are no known pharmacokinetic differences related to gender or race.

Pharmacokinetics

Absorption: Lamivudine is absorbed rapidly, with a maximum lamivudine concentration of 0.5 to 1.5 hours following oral dose administration and absolute bioavailability of approximately 82% in adults and 68% in children.[11] Lamivudine can be taken with or without food. While systemic exposure to lamivudine does not change with food intake, taking lamivudine with food slows the absorption rate by 40%. Lamivudine is manufactured as an oral liquid and tablet form and has equitable bioavailability in adults. The solid tablet is preferred in children because bioavailability is 40% lower in children using the oral liquid form. While both doses of the solid tablet have similar steady-state concentrations and therapeutic effects, the larger dose of 300 mg once daily has shown to have larger trough and maximum serum levels and is less consistent throughout the day than the smaller 150 mg tablet taken twice daily.

Distribution: Lamivudine is distributed into the total body fluid/extravascular spaces. The half-life can be as long as 15.5 hours for HIV-infected cells and 19 hours for HBV-infected cells.[4] However, viral replication site reservoirs showed varying pharmacokinetics. Lamivudine has been shown to have a longer half-life and higher IC50 after the first dose in seminal mononuclear cells and the female genital tract.[14] Conversely, the cerebral spinal fluid has shown minimal transmission of lamivudine across the blood-brain barrier, especially in adults.[15][16] Lamivudine freely traverses the placenta, often presenting with exceedingly high concentrations, and is readily found in breast milk.

Metabolism: Lamivudine does not undergo metabolism via the CYP450 pathway and minimally binds to plasma protein. Therefore, CYP450 inducers and inhibitors will not affect its metabolism, nor does the drug have many drug interactions with protein-bound medications. While lamivudine has some drug-drug interactions, like interferon-α blockers, ribavirin, zidovudine, and drugs that inhibit MATE-1, MATE-2K, OCT2 transporters, like trimethoprim and indinavir, which increases the plasma concentration of lamivudine, no interactions have clinical significance.[17] One exception is sorbitol, which demonstrates dose-dependent decreases in the maximum serum concentration of lamivudine.

Elimination: Lamivudine is eliminated in the urine and secreted as an active organic cation. The mean elimination half-life was 5 to 7 hours.[11] The average clearance of unaltered lamivudine is 71%, with 5% to 10% excreted as trans-sulfoxide.[11][18] This clearance indicates the necessity for sufficient kidney function in the patient, and dosing should be adjusted accordingly. Dialysis did not significantly increase the elimination of lamivudine to warrant dose modification. Pregnant women have a 22% increase in lamivudine clearance without leading to sub-exposure.[18][19]

Administration

Dosage Forms and Strengths

Lamivudine is available in 150 mg scored tablets, 300 mg tablets, and 5 mg/mL or 10 mg/mL oral solutions. Lamivudine may be taken with or without food and should be stored at room temperature. The patient should take a missed dose when remembering, but doses should not be doubled.

Care is necessary if the patient resists other previously prescribed antiviral medications. Chronic co-administration with sorbitol should be avoided to prevent a decrease in lamivudine concentration and potency. Pharmacokinetic changes are minor with ZDV, ddI, cotrimoxazole, and interferon-α-2b, so no dose adjustment is recommended.[11] 

Resistance to lamivudine, as well as cross-resistance to other NRTIs, such as didanosine, abacavir, and emtricitabine, are seen in 10% of patients after treatment with lamivudine as a monotherapy or combined therapy after 48 weeks of treatment.[2] While this can result in a virologic failure, clinical observations suggest a benefit to continuing lamivudine treatment even when an M184V substitution mutation causes resistance.[2][20]

Adult Dosing

  • HIV Infection: 300 mg orally once daily.
  • Chronic hepatitis B infection: 100 ng orally once daily. Higher doses are necessary for patients with HIV co-infection.
  • HIV post-exposure prophylaxis (off-label use)
    • <50 kg: 4 mg/kg/dose orally twice daily - maximum dose is 150 mg.
    • >50 kg: 150 mg orally twice daily or 300 mg once daily as part of a multi-drug regimen.
  • Perinatal hepatitis B infection prophylaxis: 100 mg orally once daily.

Special Patient Populations

Hepatic impairment: No dose adjustment is necessary in patients with hepatic impairment.

Renal impairment: Doses should be adjusted accordingly for the patient's kidney function:

  • Creatinine clearance greater than or equal to 50 mL/min should have a lamivudine dose of 150 mg twice per day or 300 mg once per day.
  • Creatinine clearance of 30 to 49 mL/min should have a lamivudine dose of 150 mg once per day. If a patient's creatinine clearance is between 15 to 29 mL/min, they should receive 150 mg as a first dose, then 100 mg daily afterward.
  • Creatinine clearance of 5 to 14 mL/min equates to 150 mg as a first dose, then 50 mg daily afterward.
  • With a creatinine clearance of less than 5 mL/min, the patient would receive 50 mg as the first dose and then 25 mg per day. Additional dosing is not necessary after either 4-hour routine hemodialysis or peritoneal dialysis.

Pregnant women: Lamivudine is currently an FDA Category C drug. The benefits outweigh the risks during pregnancy; no known teratogenicity risk exists based on limited human data. There is a potential risk of neonatal mitochondrial dysfunction and anemia based on limited human data.

Breastfeeding women: HIV patients should avoid breastfeeding because of the postnatal HIV infection, irrespective of maternal HIV treatment. No human data exists to assess lamivudine's effects on milk production. Patients with hepatitis B should avoid breastfeeding if they have cracked or bleeding nipples. Otherwise, lamivudine use while breastfeeding is acceptable.

Pediatric patients: Pediatric patients should be able to swallow tablets safely and use a separate dosing schedule. If the child cannot swallow the tablet, the oral solution dosage may need to increase because of the decrease in bioavailability. There is an increased risk of resistance when administering the oral solution to pediatric patients, so tablets are preferred whenever possible.

Older patients: Research has concluded that lamivudine therapy is efficacious and well-tolerated in older patients with chronic HBV infection.[21]

Adverse Effects

Severe adverse effects include:

  • Pancreatitis, particularly in children
  • Hepatic decompensation
  • Peripheral neuropathy
  • Muscle pain
  • Weakness
  • Aplastic anemia
  • Lactic acidosis with hepatomegaly and steatosis
  • Stevens-Johnson syndrome*
  • Immune reconstruction syndrome
  • Fat redistribution

*Patients with HIV are already at a higher risk of acquiring Stevens-Johnson syndrome (SJS). Combined therapies also make it difficult to discern if one drug alone contributed to SJS or not. No direct cases appear in the literature.

Severe adverse effects occurred in about 5% of patients enrolled in all clinical trials. Children seemed to show a higher prevalence of fever and pancreatitis than adult patients.[22]

Several case studies have shown that lamivudine can cause unusual adverse effects like thrombocytopenia and paronychia.[23][24]

Common adverse effects:

  • Headache
  • Nausea
  • Vomiting
  • Diarrhea
  • Weight loss
  • Abdominal pain
  • Fever
  • Cough and nasal signs and symptoms

Drug-Drug Interactions

Concurrent lamivudine use should be avoided with the following drugs:

  • Abacavir: avoid concurrent use of abacavir oral solution with lamivudine oral solution, as the combination may decrease lamivudine efficiency.
  • Betibeglogene autotemcel or elivaldogene autoemcel: Lamivudine should be discontinued for at least 1 month prior to starting therapy with betibeglogene autotemcel or elivaldogene autoemcel, as it may interfere with gene transfer into apheresed cells.
  • Cladribine: Combination may increase cladribine levels by inhibiting intracellular phosphorylation.
  • Bictegravir: Duplicate therapy and potential to increase lamivudine levels.
  • Tafenoquine: This combination may increase lamivudine levels, possibly through inhibition of renal transport.

The above is not a complete list. As always, a thorough medication reconciliation should take place whenever pharmaceutical therapy is started or modified.

Contraindications

Lamivudine should not be administered to patients with known hypersensitivity. Avoid concurrent sorbitol-containing product use when dosing the oral solution formulation.

Box Warning

There is an FDA Box Warning for lamivudine:

  • There are reports of lactic acidosis and severe hepatomegaly with steatosis, including fatalities, in patients using nucleoside analogs.
  • Reports exist of hepatitis B exacerbations in patients co-infected with HBV and HIV-1 who have discontinued lamivudine. These patients require hepatic function monitoring and initiation of hepatitis B therapy when necessary.
  • HIV-1-infected patients should only receive lamivudine dosage forms approved for HIV-1 treatment.

Monitoring

As a class, NRTIs have more cases of resulting hepatomegaly, with some fatalities. Lactic acidosis, a typical NRTI toxicity, is not seen as frequently with lamivudine. However, severely overweight females who have been on immunotherapy for an extended time seem to be at an increased risk. If a patient presents with symptoms, lamivudine should be discontinued immediately.[25] Additionally, the patient's liver function should be considered before beginning lamivudine; those with liver disease should rank as high risk.

Patients treated with interferon-α inhibitors with or without ribavirin when they are co-infected with HCV should be monitored closely for liver toxicities, especially hepatic decompensation, due to their pyrimidine phosphorylation reduction effects. If decompensation or increased liver toxicity occurs, interferon-α inhibitors with or without ribavirin should be decreased or discontinued.

Patients using lamivudine for HBV should receive testing for HIV-1, and patients with HIV-1 should be tested for HBV. If the patient has a co-infection, the lower dose of lamivudine (EPIVIR-HBV) is not adequate for patients and could lead to increased antiviral resistance of either virus for both adults and children.[26][27] Patients should not discontinue lamivudine while co-infected with HIV-1 and HBV. Severe, acute hepatitis B exacerbation can occur. Hepatic function (ALT levels) should be closely monitored for several months after stopping treatment, and initiation of anti-hepatitis B treatment may be appropriate with physician-guided discontinuation.

CD4+ cell count and viral load should have frequent checking to determine HIV-1 disease progression and efficacy and extent of virologic failure resulting in lamivudine resistance in combination therapy.[28] Patients should also receive monitoring for the development of inflammatory responses to opportunistic infections commonly seen in HIV patients (mycobacterium avium, CMV, PCP, TB) as well as autoimmune disorders within the first few months of starting combination antiviral therapy, including lamivudine as symptoms of immune reconstitution syndrome. 

Kidney indicators require monitoring throughout treatment, especially in chronic kidney disease (CKD) patients. CKD is a natural outcome of aging, so special attention may be necessary in treating older patients.

Pediatric patients who have a history of antiviral therapy or a history of pancreatitis need monitoring for lamivudine-induced pancreatitis. Pediatric patients should also know to avoid sorbitol-containing medicines when using oral lamivudine because antiviral resistance and lower virologic suppression rates can occur due to lower plasma lamivudine exposure.[22][29]

Fat redistribution in a "cushingoid appearance," lipoatrophy, and insulin resistance should also be monitored in patients using NRTIs.[30]

Toxicity

Lamivudine is usually well tolerated with milder toxicities compared to other NRTIs.[31] If an overdose of lamivudine occurs, supportive care should be provided with monitoring. Dialysis is not a reliable treatment for an overdose of lamivudine. No human trials to date have shown evidence of carcinogenesis, mutagenesis, or fertility impairment.

Enhancing Healthcare Team Outcomes

Proper patient education on dosage, monitoring, and stopping treatment will help improve outcomes. Proper clinician education on prescribing considerations, including comorbidities, monitoring, adherence to treatment regimens, and stopping treatment, is also necessary. Care is essential when prescribing the oral solution for pediatric patients due to the possibility of pancreatitis or worsening existing pancreatitis. Consideration is also required when prescribing the correct formula for the proper condition(s). A lower dose of lamivudine is indicated for patients with HBV only. If a patient is co-infected with HIV-1, a larger dose of lamivudine is necessary to prevent HIV-1 mutation and resistance. Additionally, co-administered sorbitol-containing medicines should be avoided to limit the sub-exposure of medication.

All these factors require the efforts of an interprofessional healthcare team that includes physicians, specialists (particularly with infectious disease and HIV specialized training), advanced practice practitioners, nursing staff, and pharmacists, collaborating so that lamivudine and other antiviral measures can be optimized and issues that can limit therapeutic effectiveness avoided. This will result in better patient outcomes with fewer adverse events.

Review Questions

References

1.
Roussos A, Koilakou S, Kalafatas I, Kalantzis C, Apostolou N, Grivas E, Raptis N, Mantzaris G. Lamivudine treatment for acute severe hepatitis B: report of a case and review of the literature. Acta Gastroenterol Belg. 2008 Jan-Mar;71(1):30-2. [PubMed: 18396747]
2.
Quercia R, Perno CF, Koteff J, Moore K, McCoig C, St Clair M, Kuritzkes D. Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr. 2018 Jun 01;78(2):125-135. [PMC free article: PMC5959256] [PubMed: 29474268]
3.
Haché C, Villeneuve JP. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother. 2006 Sep;7(13):1835-43. [PubMed: 16925509]
4.
Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):105-14. [PubMed: 20001611]
5.
Miller V, Stark T, Loeliger AE, Lange JM. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 2002 Apr;3(2):135-45. [PubMed: 12010361]
6.
Casado JL, Bañón S. Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection. Expert Rev Clin Pharmacol. 2015;8(6):709-18. [PubMed: 26517111]
7.
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997 May 17;349(9063):1413-21. [PubMed: 9164314]
8.
Radford M, Parks DC, Ferrante S, Punekar Y. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. AIDS. 2019 Sep 01;33(11):1739-1749. [PMC free article: PMC6686958] [PubMed: 31180906]
9.
Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ., GARDEL Study Group. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014 Jul;14(7):572-80. [PubMed: 24783988]
10.
Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, Lim B, Stanton LW. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004 Apr;10(4):581-6. [PMC free article: PMC3323075] [PubMed: 15200845]
11.
Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999 Jan;36(1):41-66. [PubMed: 9989342]
12.
Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther. 2007;12(7):1075-85. [PubMed: 18018766]
13.
Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012 Oct;92(4):414-7. [PMC free article: PMC3660037] [PubMed: 22992668]
14.
Dumond JB, Yang KH, Kendrick R, Reddy YS, Kashuba AD, Troiani L, Bridges AS, Fiscus SA, Forrest A, Cohen MS. Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. Antimicrob Agents Chemother. 2015 Oct;59(10):6395-401. [PMC free article: PMC4576057] [PubMed: 26239974]
15.
Gray LR, Tachedjian G, Ellett AM, Roche MJ, Cheng WJ, Guillemin GJ, Brew BJ, Turville SG, Wesselingh SL, Gorry PR, Churchill MJ. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013;8(4):e62196. [PMC free article: PMC3628669] [PubMed: 23614033]
16.
Van den Hof M, Blokhuis C, Cohen S, Scherpbier HJ, Wit FWNM, Pistorius MCM, Kootstra NA, Teunissen CE, Mathot RAA, Pajkrt D. CNS penetration of ART in HIV-infected children. J Antimicrob Chemother. 2018 Feb 01;73(2):484-489. [PubMed: 29126299]
17.
Müller F, König J, Hoier E, Mandery K, Fromm MF. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol. 2013 Sep 15;86(6):808-15. [PubMed: 23876341]
18.
Johnson MA, Verpooten GA, Daniel MJ, Plumb R, Moss J, Van Caesbroeck D, De Broe ME. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol. 1998 Jul;46(1):21-7. [PMC free article: PMC1873976] [PubMed: 9690945]
19.
Benaboud S, Tréluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, Rey E, Pannier E, Firtion G, Launay O, Hirt D. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother. 2012 Feb;56(2):776-82. [PMC free article: PMC3264256] [PubMed: 22106227]
20.
Götte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol. 2000 Apr;74(8):3579-85. [PMC free article: PMC111867] [PubMed: 10729133]
21.
Kawaoka T, Suzuki F, Akuta N, Suzuki Y, Arase Y, Sezaki H, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, Kumada H. Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection. J Gastroenterol. 2007 May;42(5):395-401. [PubMed: 17530365]
22.
Perry CM, Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 1997 Apr;53(4):657-80. [PubMed: 9098665]
23.
Lebensztejn DM, Kaczmarski M. Lamivudine-associated thrombocytopenia. Am J Gastroenterol. 2002 Oct;97(10):2687-8. [PubMed: 12385471]
24.
Zerboni R, Angius AG, Cusini M, Tarantini G, Carminati G. Lamivudine-induced paronychia. Lancet. 1998 Apr 25;351(9111):1256. [PubMed: 9643757]
25.
Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS. 2007 Nov 30;21(18):2455-64. [PubMed: 18025882]
26.
Ba A, Ndiaye FK, Djeng YJ, Cames C, Diack A, N'diaye O. Impact of Highly Active Antiretroviral Therapy on Chronic Hepatitis B Serological Markers among Senegalese HIV Co-infected Children. Int J MCH AIDS. 2019;8(2):131-137. [PMC free article: PMC6895772] [PubMed: 31824751]
27.
Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat. 2001 Apr;4(2):118-28. [PubMed: 11512520]
28.
Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES., AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009 Dec 03;361(23):2230-40. [PMC free article: PMC2800041] [PubMed: 19952143]
29.
Adkison K, Wolstenholme A, Lou Y, Zhang Z, Eld A, Perger T, Vangerow H, Hayward K, Shaefer M, McCoig C. Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study. Clin Pharmacol Ther. 2018 Mar;103(3):402-408. [PMC free article: PMC5836851] [PubMed: 29150845]
30.
McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, Myers L, Melbourne K, Ha B, Daar ES. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011 Jul 15;53(2):185-96. [PMC free article: PMC3165963] [PubMed: 21690627]
31.
Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhøj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996 Jul 10;276(2):111-7. [PubMed: 8656502]

Disclosure: Katherine Taylor declares no relevant financial relationships with ineligible companies.

Disclosure: Kristina Fritz declares no relevant financial relationships with ineligible companies.

Disclosure: Mark Pellegrini declares no relevant financial relationships with ineligible companies.

Disclosure: Mayur Parmar declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK559252PMID: 32644678

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

  • Zidovudine.[StatPearls. 2024]
    Zidovudine.
    Edwards Z, Ingold CJ, Azmat CE. StatPearls. 2024 Jan
  • Reverse Transcriptase Inhibitors.[StatPearls. 2024]
    Reverse Transcriptase Inhibitors.
    Patel PH, Zulfiqar H. StatPearls. 2024 Jan
  • Tacrolimus.[StatPearls. 2024]
    Tacrolimus.
    Araya AA, Tasnif Y. StatPearls. 2024 Jan
  • Benazepril.[StatPearls. 2024]
    Benazepril.
    Dahal SS, Gupta M. StatPearls. 2024 Jan
  • Etoposide.[StatPearls. 2024]
    Etoposide.
    Reyhanoglu G, Tadi P. StatPearls. 2024 Jan
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...